Search Results - peter+kwong

9 Results

Sort By:

Abstract: Lassa Hemorrhagic Fever (LHF) is a serious disease caused by infection with Lassa virus (LASV) – highly prevalent in West Africa and spreading globally. LASV is associated with high morbidity and mortality rates, annually infecting 100,000 to 300,000 individuals and causing 5,000 deaths. Developing prophylactics and treatment for LASV is difficult...

Published: 5/21/2024 | Inventor(s): Mitchell Ho, Peter Kwong, Zhijian Duan, Yaping Sun, Sao Cheung, Jason Gorman

Keywords(s): antibodies, diagnostic, HO, LASSA, Lassa Hemorrhagic Fever, LHF, Nanobodies, Neutralizing, virus

Category(s): Application > Therapeutics, Collaboration Sought > Collaboration, Collaboration Sought > Licensing, TherapeuticArea > Infectious Disease

Resurfaced Stabilized Core 3 (RSC3) Protein, Derived Proteins, and DNA Encoding These Proteins: RSC3, RSC3 delta371I, RSC3 delta371I/P363N, RSC3 G367R

Details for these materials may be found in the NIH AIDS Reagent Program Catalog – RSC3 (Catalog# 12042): https://www.aidsreagent.org/reagentdetail.cfm?t=proteins&id=214 RSC3 delta371I (Catalog# 12043): https://www.aidsreagent.org/reagentdetail.cfm?t=proteins&id=146 RSC3 delta371I/P363N (Catalog# 12362): https://www.aidsreagent.org/reagentdetail.cfm?t=proteins&id=145 RSC3...

Published: 7/25/2024 | Inventor(s): Tongqing Zhou, Gary Nabel, Zhi-yong Yang, Ling Xu, Peter Kwong

Keywords(s): 3, Core, DERIVED, DNA, Encoding, Protein, proteins, Resurfaced, RM, RSC3, Stabilized, THESE, WIXXXX

Category(s): Collaboration Sought > Licensing, Collaboration Sought > Materials Available, Application > Research Materials

Stabilized Influenza Hemagglutinin Stem Region Trimers and Uses Thereof

An effective universal influenza vaccine would eliminate the uncertain and costly process of seasonal influenza vaccine development each year. Researchers at the National Institute of Allergy and Infectious Diseases (NIAID) are developing immunogens which elicit neutralizing antibodies to the highly conserved stem region of the influenza viral protein...

Published: 7/25/2024 | Inventor(s): Jeffrey Boyington, Hadi Yassine, Peter Kwong, Masaru Kanekiyo, Barney Graham, John Mascola

Keywords(s): Broad, Development, ELICIT, HEMAGGLUTININ, IMMUNE, INFLUENZA, Listed LPM Thalhammer-Reyero as of 4/15/2015, Modified, Nanoparticles, Post LPM Assignment Set 20150420, Pre LPM working set 20150418, RESPONSE, Stem

Category(s): Collaboration Sought > Licensing

Neutralizing Antibodies to Influenza HA and Their Use and Identification

The effectiveness of current influenza vaccines varies by strain and season, in part because influenza viruses continuously evolve to evade human immune responses. While the majority of seasonal influenza infections cause relatively mild symptoms, each year influenza virus infections result in over 500,000 hospitalizations in the United States and Europe....

Published: 7/25/2024 | Inventor(s): Robert Bailer, Michael Joyce, John Mascola, Peter Kwong, Sarah Andrews, Paul Thomas, Gwo-Yu Chuang, Adam Wheatley, Yi Zhang, James Whittle, Adrian McDermott

Keywords(s): 1, 2, antibodies, DB4XXX, DBXXXX, DC5XXX, DCXXXX, DXXXXX, GROUP, INFLUENZA, Neutralize, That, Their, Viruses, VLXXXX, WJXXXX, WNXXXX, XAXXXX, XKXXXX, YCXXXX

Category(s): Collaboration Sought > Licensing, Application > Therapeutics, Application > Vaccines, TherapeuticArea > Infectious Disease, ResearchProducts > Antibodies, TherapeuticArea > Immunology

Broadly Neutralizing Antibodies Against HIV-1 Directed to the CD4 Binding Site of HIV Envelope Protein

Inhibiting the ability of HIV-1, the virus that causes AIDS, to infect cells is one approach to both prevention and treatment of HIV. Scientists at the NIAID Vaccine Research Center have isolated and characterized neutralizing antibodies (VRC01, 02, 03, and 07) that bind to the CD4 binding site of HIV-1 envelope glycoprotein gp120. These human monoclonal...

Published: 7/25/2024 | Inventor(s): Richard Wyatt, Xueling Wu, Yuxing Li, Carl-Magnus Hogerkorp, Mario Roederer, Zhi-yong Yang, Gary Nabel, Peter Kwong, Tongqing Zhou, Mark Connors, Gilad Ofek, Yongping Yang, Jiang Zhu, Lawrence Shapiro, William Schief, Rebecca Rudicell, Ivelin Georgiev, Young Do Kwon, Baoshan Zhang, Gwo-yu Chauang, Wei Shi, Gwo-Yu Chuang, John Mascola

Keywords(s): Against, antibodies, Antibodies., ANTIBODY, Antibody-based, B-Cells, Broadly, Chain, Constructs, CREATION, DA4AXX, DB4AXX, DC5AXX, DD2XXX, Epitope-Specific, Expressing, FUNCTION, Further, GENERAL, GLYCOPROTEIN, gp120, HIV, HIV-1, Identity, Immunoadesion, Immunoadhesin, Isolation, Listed LPM Thalhammer-Reyero as of 4/15/2015, MODE, Modifications, monoclonal, Monoco, Neutizing, Neutralization, Neutralizing, Novel, Patent Category - Biotechnology, Post LPM Assignment Set 20150420, Pre LPM working set 20150418, Probes, Single, Specific, VRC03, VRC03Isolation

Category(s): Collaboration Sought > Licensing, Application > Therapeutics, Application > Vaccines, TherapeuticArea > Infectious Disease, Application > Diagnostics, Application > Research Materials

Recombinant Stabilized Prefusion Protein of Respiratory Syncytial Virus for Use as a Subunit Vaccine

The invention, a stabilized recombinant prefusion F protein (pre F), is a candidate subunit vaccine for Respiratory Syncytial Virus (RSV). Pre-F is stabilized in the prefusion conformation and displays epitopes not present in postfusion F protein. Several potent RSV neutralizing antibodies bind pre F, but not postfusion F. Therefore, immunization...

Published: 7/25/2024 | Inventor(s): Jason Gorman, Gilad Ofek, Marie Pancera, Mallika Sastry, Sanjay Srivatsan, Yongping Yang, Lei Chen, Cinque Soto, Tongqing Zhou, Barney Graham, Peter Kwong, Masaru Kanekiyo, Michael Joyce, Baoshan Zhang, Guillaume Stewart-Jones, Jeffrey Boyington, Man Chen, Gwo-Yu Chuang, Ivelin Georgiev, Jason McLellan

Keywords(s): CONFORMATION, DC5BXX, DC5XXX, DCXXXX, DXXXXX, F, GLYCOPROTEIN, Listed LPM Thalhammer-Reyero as of 4/15/2015, Post LPM Assignment Set 20150420, Pre LPM working set 20150418, Prefusion, PrefusionConformation, RSV, Stabilization, Structure-based, Vaccine, VLXXXX, YCXXXX

Category(s): Collaboration Sought > Licensing, Application > Vaccines, TherapeuticArea > Infectious Disease

N6, A Novel, Broad, Highly Potent HIV-specific Antibody

This is a new antibody coming out of NIAID’s intramural program. N6 has evolved a unique mode of binding that depends less on a variable area of the HIV envelope known as the V5 region and focuses more on conserved regions, which change relatively little among HIV strains. This allows N6 to tolerate changes in the HIV envelope, including the attachment...

Published: 7/25/2024 | Inventor(s): Jinghe Huang, Byong Kang, John Mascola, Elise Ishida, Tongqing Zhou, Anqi Zheng, Peter Kwong, Mark Connors

Keywords(s): ANTIBODY, bNAb, Broad, Highly, HIV-soecific, HIV-Specific, Listed LPM Thalhammer-Reyero as of 4/15/2015, N6, Novel, Ootent, Post LPM Assignment Set 20150420, POTENT, Pre LPM working set 20150418

Category(s): Collaboration Sought > Collaboration

Broadly Neutralizing Human Anti-HIV Monoclonal Antibody 10E8 and Related Antibodies Capable of Neutralizing Most HIV-1 Strains

The uses for human anti-HIV monoclonal antibody 10E8 and its variants include passive immunization, therapeutic vaccination, and the development of vaccine immunogens. 10E8 is one of the most potent HIV-neutralizing antibodies isolated and it neutralizes up to 98% of diverse HIV-1 strains. 10E8 is specific to the membrane-proximal external region (MPER)...

Published: 7/25/2024 | Inventor(s): John Mascola, Leo Laub, Jinghe Huang, Peter Kwong, Gilad Ofek, Jiang Zhu, Gary Nabel, Ivelin Georgiev, Yongping Yang, Rebecca Rudicell, Mark Connors

Keywords(s): antibodies, ANTIBODY, ANTI-HIV, Anti-HIV-1, Anti-HIV-l, Broadly Neutralizing Antibody, DB4AXX, DB4XXX, DBXXXX, DC5AXX, DC5XXX, DCXXXX, DXXXXX, gp41, Human, ISOLATING, Knowledge, mabs, Membrane-Proximal, Method, monoclonal, Neutralizing, prior, Producing, Specificity, VLXXXX, WITHOUT, WJXXXX, XAXXXX, YBXXXX, YCXXXX

Category(s): Collaboration Sought > Collaboration, TherapeuticArea > Infectious Disease, TherapeuticArea > Immunology, ResearchProducts > Antibodies, Application > Therapeutics, Application > Vaccines

Novel System for HIV-1 Vaccine Development

The available technologies describe specific immunogenic peptides, peptide modifications and methods for identifying additional immunogens against HIV-1 surface proteins, gp120 and gp41. Additionally, detailed methods for use of the described immunogenic peptides in the development of vaccines and diagnostics for HIV-1 are disclosed. The current technologies...

Published: 7/25/2024 | Inventor(s): Peter Kwong

Keywords(s): Against, ANTIGENIC, Anti-HIV-1, ATOMIC, Biotechnology, Broadly, CONFORMATIONALLY, Cryptic, DC5AXX, DC5XXX, DCXXXX, DEFINITION, Details, DXXXXX, Ectodomain, ELICIT, Envelope, Epitope, Epitopes, Epitope-transplant, FUNCTION, Gp120:, gp41, HIV, HIV-1, Immunization, IMMUNOGENS, Level, Membrane-Proximal, Neutralizing, Patent Category - Biotechnology, Reveal, Scaffolds, Stabilized, Strategies, structure, Their, Triggering, V3-Loop, Vaccine

Category(s): Collaboration Sought > Licensing, TherapeuticArea > Infectious Disease, Application > Vaccines